Mode of action for inorganic arsenic toxicity and carcinogenesis

Puttappa R. Dodmane, Lora L Arnold, Samuel Monroe Cohen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inorganic arsenic (iAs) at high doses is a known human carcinogen, inducing tumors of the skin, urinary bladder, and lung. It is also associated with noncancer toxicities. An understanding of the mode of action (MOA) for arsenic-induced effects is needed to develop a scientifically-based risk assessment. To determine an MOA for iAs induced toxicities, it is necessary to understand the metabolism, kinetics, cell transport, and interaction with specific proteins of iAs. Based on in vitro investigations using animal and human cells, studies from animal models, and clinical and epidemiological studies, we have proposed an MOA involving formation of sufficient levels of reactive trivalent metabolites which interact with critical free sulfhydryl groups, leading to cytotoxicity and regenerative cell proliferation. There is a strong correlation between in vitro cytotoxicity ([0.1 lmol/L trivalent arsenicals) and the no effect levels in rodents [approximately 1 ppm (1 ppm = 1 mg/L) of water or diet]. In epithelial target tissues, the cytotoxic effects of iAs result in chronic precursor lesions which have the potential for an increased risk of developing cancer. In non-epithelial tissues, noncancer toxicities such as hypertension and atherosclerosis develop. This MOA implies a non-linear, threshold dose– response relationship for both non-cancer and cancer end points of exposure to iAs.

Original languageEnglish (US)
Pages (from-to)1078-1082
Number of pages5
JournalChinese Science Bulletin
Volume59
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Arsenic
Carcinogenesis
Arsenicals
Neoplasms
Cell Communication
Carcinogens
Epidemiologic Studies
Rodentia
Atherosclerosis
Urinary Bladder
Epithelium
Animal Models
Cell Proliferation
Diet
Hypertension
Lung
Skin
Water
Proteins

Keywords

  • Arsenic
  • Cell proliferation
  • Cytotoxicity
  • Mode of action

ASJC Scopus subject areas

  • General

Cite this

Mode of action for inorganic arsenic toxicity and carcinogenesis. / Dodmane, Puttappa R.; Arnold, Lora L; Cohen, Samuel Monroe.

In: Chinese Science Bulletin, Vol. 59, No. 11, 01.11.2014, p. 1078-1082.

Research output: Contribution to journalArticle

@article{753cbc00068b4faa949040aa3ed6c02d,
title = "Mode of action for inorganic arsenic toxicity and carcinogenesis",
abstract = "Inorganic arsenic (iAs) at high doses is a known human carcinogen, inducing tumors of the skin, urinary bladder, and lung. It is also associated with noncancer toxicities. An understanding of the mode of action (MOA) for arsenic-induced effects is needed to develop a scientifically-based risk assessment. To determine an MOA for iAs induced toxicities, it is necessary to understand the metabolism, kinetics, cell transport, and interaction with specific proteins of iAs. Based on in vitro investigations using animal and human cells, studies from animal models, and clinical and epidemiological studies, we have proposed an MOA involving formation of sufficient levels of reactive trivalent metabolites which interact with critical free sulfhydryl groups, leading to cytotoxicity and regenerative cell proliferation. There is a strong correlation between in vitro cytotoxicity ([0.1 lmol/L trivalent arsenicals) and the no effect levels in rodents [approximately 1 ppm (1 ppm = 1 mg/L) of water or diet]. In epithelial target tissues, the cytotoxic effects of iAs result in chronic precursor lesions which have the potential for an increased risk of developing cancer. In non-epithelial tissues, noncancer toxicities such as hypertension and atherosclerosis develop. This MOA implies a non-linear, threshold dose– response relationship for both non-cancer and cancer end points of exposure to iAs.",
keywords = "Arsenic, Cell proliferation, Cytotoxicity, Mode of action",
author = "Dodmane, {Puttappa R.} and Arnold, {Lora L} and Cohen, {Samuel Monroe}",
year = "2014",
month = "11",
day = "1",
doi = "10.1007/s11434-014-0150-8",
language = "English (US)",
volume = "59",
pages = "1078--1082",
journal = "Science Bulletin",
issn = "2095-9273",
publisher = "Springer Science + Business Media",
number = "11",

}

TY - JOUR

T1 - Mode of action for inorganic arsenic toxicity and carcinogenesis

AU - Dodmane, Puttappa R.

AU - Arnold, Lora L

AU - Cohen, Samuel Monroe

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Inorganic arsenic (iAs) at high doses is a known human carcinogen, inducing tumors of the skin, urinary bladder, and lung. It is also associated with noncancer toxicities. An understanding of the mode of action (MOA) for arsenic-induced effects is needed to develop a scientifically-based risk assessment. To determine an MOA for iAs induced toxicities, it is necessary to understand the metabolism, kinetics, cell transport, and interaction with specific proteins of iAs. Based on in vitro investigations using animal and human cells, studies from animal models, and clinical and epidemiological studies, we have proposed an MOA involving formation of sufficient levels of reactive trivalent metabolites which interact with critical free sulfhydryl groups, leading to cytotoxicity and regenerative cell proliferation. There is a strong correlation between in vitro cytotoxicity ([0.1 lmol/L trivalent arsenicals) and the no effect levels in rodents [approximately 1 ppm (1 ppm = 1 mg/L) of water or diet]. In epithelial target tissues, the cytotoxic effects of iAs result in chronic precursor lesions which have the potential for an increased risk of developing cancer. In non-epithelial tissues, noncancer toxicities such as hypertension and atherosclerosis develop. This MOA implies a non-linear, threshold dose– response relationship for both non-cancer and cancer end points of exposure to iAs.

AB - Inorganic arsenic (iAs) at high doses is a known human carcinogen, inducing tumors of the skin, urinary bladder, and lung. It is also associated with noncancer toxicities. An understanding of the mode of action (MOA) for arsenic-induced effects is needed to develop a scientifically-based risk assessment. To determine an MOA for iAs induced toxicities, it is necessary to understand the metabolism, kinetics, cell transport, and interaction with specific proteins of iAs. Based on in vitro investigations using animal and human cells, studies from animal models, and clinical and epidemiological studies, we have proposed an MOA involving formation of sufficient levels of reactive trivalent metabolites which interact with critical free sulfhydryl groups, leading to cytotoxicity and regenerative cell proliferation. There is a strong correlation between in vitro cytotoxicity ([0.1 lmol/L trivalent arsenicals) and the no effect levels in rodents [approximately 1 ppm (1 ppm = 1 mg/L) of water or diet]. In epithelial target tissues, the cytotoxic effects of iAs result in chronic precursor lesions which have the potential for an increased risk of developing cancer. In non-epithelial tissues, noncancer toxicities such as hypertension and atherosclerosis develop. This MOA implies a non-linear, threshold dose– response relationship for both non-cancer and cancer end points of exposure to iAs.

KW - Arsenic

KW - Cell proliferation

KW - Cytotoxicity

KW - Mode of action

UR - http://www.scopus.com/inward/record.url?scp=84919451838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919451838&partnerID=8YFLogxK

U2 - 10.1007/s11434-014-0150-8

DO - 10.1007/s11434-014-0150-8

M3 - Article

AN - SCOPUS:84919451838

VL - 59

SP - 1078

EP - 1082

JO - Science Bulletin

JF - Science Bulletin

SN - 2095-9273

IS - 11

ER -